ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0635

Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus

Sarah Lieber1, Neha Nagpal1, Julia Nguyen2, Ashley Chung2, Dongmei Sun1, John Carrino3, M. Carrington Reid4 and Lisa Mandl1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Department of Radiology and Imaging, Hospital for Special Surgery, New York, NY, 4Weill Cornell Medicine, New York, NY

Meeting: ACR Convergence 2025

Keywords: body composition, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Sarcopenia, i.e., loss of skeletal muscle mass and strength, has been associated with multiple adverse health outcomes, including mortality. We have previously demonstrated associations of the SARC-F, a simple self-report screening tool for sarcopenia, with functional outcomes in adults with systemic lupus erythematosus (SLE). However, to our knowledge, whether the SARC-F is associated with objective measures of sarcopenia in patients with SLE has not been explored [1]. Accordingly, this study sought to assess the association of the SARC-F with dual energy x-ray absorptiometry (DXA)-based definitions of sarcopenia.

Methods: Women 18-70 years of age with validated SLE were enrolled in a single-center cross-sectional study. Sociodemographic characteristics, clinical features, and the SARC-F (which includes questions on strength, assistance walking, rising from a chair, climbing stairs, and falls) were self-reported or collected from the patient’s electronic medical record. Disease activity and damage were provided by treating physicians. Sarcopenia was measured via DXA using 4 consensus definitions. Descriptive statistics were used to compare sociodemographic characteristics, clinical features, SLE disease severity, and objective measures of sarcopenia between participant groups. SARC-F scores were dichotomized as ≥4 (i.e., at risk for sarcopenia) versus < 4 (i.e., not at risk for sarcopenia) based on established cut points. Fisher’s exact tests evaluated the relationship between the SARC-F and objective measures of sarcopenia.

Results: Of 57 participants, 16 (29%) were at risk for sarcopenia based on SARC-F score ≥4 (Table 1). Participants with SARC-F ≥4 were older (p=0.02) and had greater organ damage (p< 0.01) and slower gait speed (p< 0.01 to p=0.04) than those with SARC-F < 4 (Tables 1 and 2). Among 56 women who had DXA, there were no significant associations between the SARC-F and any of the 4 standard validated measures of objective sarcopenia (Table 3). The European Working Group on Sarcopenia in Older People definition had the highest specificity (data not shown).

Conclusion: In this exploratory study of adult women with SLE, very few participants had low muscle mass meeting DXA-based definitions of sarcopenia. In non-elderly women with SLE, DXA scores with a lower threshold for sarcopenia, without BMI adjustment (i.e., European Working Group on Sarcopenia in Older People definition), may preferentially identify those at risk for sarcopenia. Ongoing studies in larger cohorts are needed.References:1. Malmstrom et al. J Cachexia Sarcopenia Muscle 2016;7:28-36.

Supporting image 1Table 1. Sociodemographic and disease characteristics and SARC-F components of adults with systemic lupus erythematosus (SLE) with high (≥4) versus low ( < 4) SARC-F scores

Supporting image 2Table 2. Objective sarcopenia measures of adults with systemic lupus erythematosus with high (≥4) versus low ( < 4) SARC-F scores

Supporting image 3Table 3. Cross sectional association of SARC-F with objective sarcopenia definitions


Disclosures: S. Lieber: None; N. Nagpal: None; J. Nguyen: None; A. Chung: None; D. Sun: None; J. Carrino: Arthritis & Rheumatology, 12, Editorial Board, Carestream, 4, Cartilage Imaging, 12, Editorial Board, Covera, 2, Image Analysis Group, 4, Image Biopsy Lab, 4, Radiology, 12, Editorial Board; M. Reid: None; L. Mandl: ACP, 12, Associate Editor Annals of Internal Medicine, Wolters, 9.

To cite this abstract in AMA style:

Lieber S, Nagpal N, Nguyen J, Chung A, Sun D, Carrino J, Reid M, Mandl L. Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/comparison-of-the-sarc-f-with-objective-measures-of-sarcopenia-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-sarc-f-with-objective-measures-of-sarcopenia-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology